Cargando…
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
A 54-year-old patient presented to his general practitioner because of strong muscle pain in both thighs. Inflammatory parameters (CRP 16.3 mg/dL) and white blood cells (15 g/L) were elevated. The patient reported a weight loss of 10 kg in 4 weeks. There was no fever or any other specific symptoms....
Autores principales: | Moog, Philipp, Thuermel, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669915/ https://www.ncbi.nlm.nih.gov/pubmed/26664125 http://dx.doi.org/10.2147/TCRM.S79080 |
Ejemplares similares
-
Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy
por: Yoneva, Tsvetelina, et al.
Publicado: (2022) -
Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022) -
The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis
por: Koukoulaki, Maria, et al.
Publicado: (2019) -
Treatment of Aggressive Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Eculizumab
por: Huizenga, Noah, et al.
Publicado: (2019) -
Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody–Associated Vasculitis: Systematic Review and Meta‐Analysis
por: Bénard, Valérie, et al.
Publicado: (2021)